TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01148017

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine
Study: NCT01765699

Intervention type: DEVICE
Intervention: Primary knee arthroplasty
Description: Patients undergoing primary knee arthroplasty
Study: NCT03928743

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimekizumab
Description: Subjects will receive bimekizumab at pre-specified time-points.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bimekizumab
Description: Subjects will receive bimekizumab at pre-specified time-points.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive placebo at pre-specified time-points during the Double-Blind Treatment Period.
Study: NCT03277261

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV Placebo
Description: Administered as an IV infusion.
Study: NCT02597010

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary nitrate
Description: 140ml of nitrate rich beetroot juice provides 12.9mmol nitrate and will be consumed on a daily basis during the intervention by the study subjects.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 140ml of nitrate depleted beetroot juice provides 0.5mmol nitrate and will be consumed on a daily basis during the intervention by the study subjects.
Study: NCT04419688

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STT-5058
Description: Monoclonal Antibody STT-5058

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo to STT-5058
Study: NCT01977703

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultra Conservative ICD Programming

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional ICD Programming
Study: NCT03019666

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nicotinamide Expanded Haploidentical or Mismatched Related Donor Natural Killer Cells
Description: * Cyclophosphamide 40 mg/kg x 1 day on Day -5~* Fludarabine 25 mg/m\^2 x 3 days (Day -5, Day -4, day-3)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nicotinamide Expanded Haploidentical or Mismatched Related Donor Natural Killer Cells
Description: * Cyclophosphamide 40 mg/kg x 1 day on Day -5~* Fludarabine 25 mg/m\^2 x 3 days (Day -5, Day -4, day-3)
Study: NCT05103124

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hydral
Description: The investigational product GUM Hydral will be administered for a 30-days treatment period
Study: NCT02430168

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous nephrolithotomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Retrograde intrarenal surgery
Study: NCT05103124

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Hydral
Description: The investigational product GUM Hydral will be administered for a 30-days treatment period

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The placebo product will be administered for a 30-days treatment period

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo product will be administered for a 30-days treatment period
Study: NCT03732534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NBI-98854
Description: vesicular monoamine transporter 2 (VMAT2) inhibitor
Study: NCT04028570

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Varying Doses of Background and Boost RT
Description: 3+3 radiation dose escalation model to see the maximum tolerated dose for background and boost radiation therapy.
Study: NCT02514434

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Ultrasonography
Description: Subjects will be randomly allocated to either Ultrasonography arm or Non-contrast MRI arm for their surveillance method.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: non-contrast MRI
Description: Subjects will be randomly allocated to either Ultrasonography arm or Non-contrast MRI arm for their surveillance method.
Study: NCT04092491

Intervention type: OTHER
Intervention: blood sample
Description: 1 blood sample during a consultation carried out as part of a medical follow-up:~* 2 PAXgene RNA tubes of 2 ml each~* 1 dry tube for creatinine and IgA assay~* 1 tube of NFs (5ml)
Study: NCT03602846

Intervention type: DIETARY_SUPPLEMENT
Intervention: Medical Nutrition Therapy
Description: Only given medical nutrition therapy.

Intervention type: DIETARY_SUPPLEMENT
Intervention: Medical Nutrition Therapy
Description: Only given medical nutrition therapy.

Intervention type: DRUG
Intervention: Insulin
Description: Prescribed with rapid acting, intermediate acting, mixed or long acting insulin.

Intervention type: DRUG
Intervention: Insulin
Description: Prescribed with rapid acting, intermediate acting, mixed or long acting insulin.

Intervention type: DRUG
Intervention: Oral Antidiabetics
Description: Prescribed with all types of oral anti-diabetics.

Intervention type: DRUG
Intervention: Oral Antidiabetics
Description: Prescribed with all types of oral anti-diabetics.
Study: NCT03511391

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab or Pembrolizumab or Atezolizumab
Description: per national standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab or Pembrolizumab or Atezolizumab
Description: per national standard of care

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: Stereotactic body radiotherapy is administered to maximally 3 lesions in 3 fractions of 8Gy prior to the second/third cycle of checkpoint inhibitors.
Study: NCT01687777

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Mesenchymal Stem Cells (MSCs)
Description: 20.000.000 autologous MSCs included in the OrthADAPT membrane. Single dosage.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: OrthADAPT
Study: NCT01790139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral simethicone
Description: 10 mL of simethicone is administered as an agent to prevent colonic bubbles
Study: NCT02226575

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A cognitive behavior therapy distress management program targeting wellbeing in patients with atrial fibrillation and their relatives
Description: Controls only delivery standard care. Experimental group deliver standard care plus a distress management program (cognitive behavioral therapy) performed in groups by a nurse, a pedagogue and a cardiologist (all trained in the distress management program).
Study: NCT04151316

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: crown preparation
Description: includes tooth preparation
Study: NCT01670929

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04151316

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: crown preparation
Description: includes tooth preparation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: vertical preparation
Description: type of vertical preparation on the tooth that accepts the crown

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: horizontal preparation
Description: type of horizontal preparation on the tooth that accepts the crown
Study: NCT05044910

Intervention type: DIETARY_SUPPLEMENT
Intervention: Ready to Use supplementary food (RUSF)
Description: Children with malnutrition will be given RUSF

Intervention type: DIETARY_SUPPLEMENT
Intervention: Ready to Use supplementary food (RUSF)
Description: Children with malnutrition will be given RUSF
Study: NCT05046275

Intervention type: OTHER
Intervention: Data analysis
Description: No intervention, data analysis only

Intervention type: OTHER
Intervention: Data analysis
Description: No intervention, data analysis only
Study: NCT00354172

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aldesleukin
Description: 10 Million units subcutaneous every other day on days -13 (after Natural killer cell graft), -11, -9, -7, -5, -3) If \< 45 kilograms (Kg) - interleukin (IL)-2 at 5 MU/m2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: All patients will receive filgrastim (same as granulocyte-colony stimulating factor or G-CSF) 5 mcg/kg/day intravenous (IV) (dose rounded to vial size) based on the actual body weight beginning on day +1 after umbilical cord blood (UCB) infusion. Granulocyte Colony Stimulating Factor (G-CSF) will be administered daily until the absolute neutrophil count (ANC) exceeds 2.5 x 10\^9/L for three consecutive days and then discontinued. If the ANC decreases to \<1.0 x 10\^9/L, G-CSF will be reinstituted.
Study: NCT00312936

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based Stress Reduction (MBSR)
Description: 8 week program
Study: NCT02435875

Intervention type: OTHER
Intervention: no intervention
Description: Antihypertensive drug as intervention is used to see if it can improve baroreflex sensitivity to stable perioperative hemodynamic

Intervention type: OTHER
Intervention: no intervention
Description: Antihypertensive drug as intervention is used to see if it can improve baroreflex sensitivity to stable perioperative hemodynamic
Study: NCT02073591

Intervention type: OTHER
Intervention: Ceradan Cream

Intervention type: OTHER
Intervention: Ceradan Wash
Study: NCT02452775

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OC-L

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OC-L

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Montanide

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Montanide

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: poly-ICLC (Hiltonol),

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: poly-ICLC (Hiltonol),
Study: NCT00354172

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: natural killer cell (NK) therapy
Description: All CD3 depleted cells will be given (less those required for product monitoring). The minimum size of a starting NK cell unit will be 700 million mononuclear cells before processing. NK cells (CD56+) and NK cell precursors (CD34+/CD7-, CD34+/CD7+, CD34-/CD7+) will be monitored and reported but will not serve as lot release.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Cyclophosphamide to be administered with high volume fluid flush and mesna on days-18 and -17 after fludarabine. Cyclophosphamide 60 mg/kg/day intravenously (IV) x 2 days, total dose 120 mg/m2 (days -18 and -17)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: Patients will receive cyclosporine (CSA) therapy beginning on day -1 maintaining a level of \>200 ng/mL. For adults the initial dose will be 2.5 mg/kg intravenously (IV) over 2 hours every 12 hours. For children \<40 kg the initial dose will be 2.5 mg/kg IV over 2 hours every 8 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Fludarabine 25 mg/m2/day intravenously (IV) x 3 days, total dose 75 mg/m2 (days -18 to -16)
Study: NCT03677609

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindset & Communication Training
Description: The mindset training is a two-hour, live training, with a one-hour follow-up one month later, that teaches care providers to recognize, shape, and leverage patient mindsets in healthcare.
Study: NCT03303547

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI mapping to guide pathological sampling of extranodal tumour deposits
Description: Radiologist to mark areas where extranodal disease is identified on MRI. The pathologist will use this to take additional samples for analysis. This will allow better pathological staging and will affect treatment decisions for patients.
Study: NCT04607889

Intervention type: OTHER
Intervention: Survey
Description: Interviews with study participants will be conducted by telephone or teleconference. The interview will focus on the participants experience with genomic tests, with the expectations, reasons for taking or declining it, hurdles encountered, satisfaction among the key themes to be discussed.

Intervention type: OTHER
Intervention: Survey
Description: Interviews with study participants will be conducted by telephone or teleconference. The interview will focus on the participants experience with genomic tests, with the expectations, reasons for taking or declining it, hurdles encountered, satisfaction among the key themes to be discussed.

Intervention type: OTHER
Intervention: Survey
Description: Interviews with study participants will be conducted by telephone or teleconference. The interview will focus on the participants experience with genomic tests, with the expectations, reasons for taking or declining it, hurdles encountered, satisfaction among the key themes to be discussed.
Study: NCT03588091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib
Description: pyrotinib: 400mg orally daily;

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: placebo: 400mg orally daily;
Study: NCT01801306

Intervention type: DEVICE
Group type: OTHER
Intervention: NeMo Probe
Description: A new minimal-invasive brain tissue probe applying near infrared spectroscopy
Study: NCT01477775

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral P2Y12 receptor blocker
Description: Free choice among clopidogrel, prasugrel or ticagrelor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Customized choice for the oral P2Y12 receptor blocker
Description: one drug among clopidogrel, prasugrel or ticagrelor based on an algorithm integrating phenotype information.
Study: NCT03353415

Intervention type: DEVICE
Group type: OTHER
Intervention: Dexcom CGM masked
Description: The CGM will monitor sensor glucose levels in all participants. (Initially the Dexcom G4 was worn by participants (n=13); however, when the G4 became unavailable, the G6 was worn by the subsequent participants (n=10)).~The duration of the Dexcom G4 sensor was 7 days (2 sensors placed during each phase of participation) versus the Dexcom G6 whose sensor duration is 10 days (1 sensor placed during each phase of participation).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dexcom CGM unmasked
Description: During the second phase (2 weeks for the Dexcom G4 and 10 days for the Dexcom G6), participants are able to see the sensor glucose levels displayed from the CGM. Participants will be instructed to use this information to treat low glucose levels before symptoms or severely low glucose levels develop.~The duration of the Dexcom G4 sensor was 7 days (2 sensors placed during each phase of participation) versus the Dexcom G6 whose sensor duration is 10 days (1 sensor placed during each phase of participation).
Study: NCT03632837

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hemoadsorption
Description: see arm description
Study: NCT02546180

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Viewing YouTube videos
Description: The on-line patient education program will highlight postoperative care.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard preoperative education
Description: Standard preoperative education will be provided by the surgeon, physician extender and paramedical staff in the clinic.
Study: NCT01013402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human insulin
Description: The test was performed in the morning after an overnight fasting and the patients remained supine during the procedure. Two intravenous lines in both arms were established before the procedure. Venous blood was obtained for serum glucose before regular insulin (0.1 U/kg ) is injected and 30 and 45 minutes thereafter. If adequate hypoglycemia was not achieved at this period, a second dose of regular insulin (0.05U/kg) was injected intravenously. In subjects who had not reached the aimed hypoglycemia levels, the test was performed in another day with a higher initial insulin dosage (0.2U/kg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human Insulin
Description: 0.1U/kg IV pulse.
Study: NCT00308230

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Six minute walk test
Study: NCT02517697

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 14 Nitrogen (N) Sodium Nitrite
Description: oral formulation of sodium nitrite 40 mg three times daily for 12 weeks
Study: NCT00308230

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Six minute walk test

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Six minute walk test

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Minnesota Living with Heart Failure Questionnaire

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Minnesota Living with Heart Failure Questionnaire

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Minnesota Living with Heart Failure Questionnaire
Study: NCT03588091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: trastuzumab:8mg/kg iv load followed by 6mg/kg iv 3-weekly for a total of 4 cycles;

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Trastuzumab
Description: trastuzumab:8mg/kg iv load followed by 6mg/kg iv 3-weekly for a total of 4 cycles;
Study: NCT02269800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benzalkonium chloride solution
Description: Tid, 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Description: Tid, 7 days
Study: NCT03588091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: docetaxel:after the biological window, 100mg/m2 for a total of 4 cycles

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Docetaxel
Description: docetaxel:after the biological window, 100mg/m2 for a total of 4 cycles
Study: NCT00856882

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: soy protein

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: isoflavones

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: isoflavones

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: milk protein

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: milk protein
Study: NCT04753008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dopamine administration
Description: Administration of dopamine (3 mcg/kg/min) as part of cardiac support therapy after the cardiopulmonary bypass. Administration of dopamine is a subject of clinical decision based on the cardiovascular status of the patients.
Study: NCT04707573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vadadustat
Description: oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vadadustat
Description: oral capsules
Study: NCT00446693

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EndoFast Reliant™ system for Pelvic Organ Prolapse repair
Description: The EndoFast Reliant™ system is a new concept of reinforcing the vaginal wall with proprietary mesh and soft-tissue Fasteners in a minimally-invasive procedure.
Study: NCT00682786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5FU

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5FU

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery of resectable lesions

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery of resectable lesions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Study: NCT02082015

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Low frequency rTMS
Description: Intensity: 100% of resting motor threshold; Location: Motor hotspot in primary motor cortex for the dominant hand; Frequency: 1Hz; Number of total stimuli: 1800; Coil orientation: tangential to scalp

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low frequency rTMS
Description: Intensity: 100% of resting motor threshold; Location: Motor hotspot in primary motor cortex for the dominant hand; Frequency: 1Hz; Number of total stimuli: 1800; Coil orientation: tangential to scalp
Study: NCT02438423

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Inactivated influenza vaccine
Description: Seasonal trivalent inactivated influenza vaccine FDA-approved for 2014-2015 influenza season

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated influenza vaccine
Description: Seasonal trivalent inactivated influenza vaccine FDA-approved for 2014-2015 influenza season
Study: NCT02517697

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral formulation of matching placebo three times daily for 12 weeks
Study: NCT00187252

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Atrial Overdrive Pacing
Description: Pacemaker/ ICD implant
Study: NCT00561600

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ASR™-XL Modular Acetabular Cup System
Description: The ASR™-XL Modular Acetabular Cup System treatment device is comprised of a metal acetabular cup, a unipolar femoral head and a taper sleeve adapter.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pinnacle™ acetabular shell
Description: The Pinnacle™ shells are cementless, titanium alloy cups with Porocoat® porous coating and HA DuoFix™ coating. There are various different liners available for use with the Pinnacle™ Acetabular Cup System. For the purpose of this investigation, the CoCrMo ULTAMET® 28mm or 36 mm metal liners will be used.
Study: NCT00187252

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Atrial Overdrive Pacing
Description: Pacemaker/ ICD implant
Study: NCT01928927

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan
Description: Participants received Telmisartan 40 mg daily during weeks 0-4 followed by telmisartan 80 mg daily during weeks 5-48.
Study: NCT02631980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV iron
Description: Intravenous iron 15 mg/kg (max 1000 mg) in 250 ml 0.9% saline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IV placebo
Description: Intravenous 0.9% saline (250 ml)
Study: NCT03415204

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: acupuncture for post operative pain
Study: NCT01522326

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Ibuprofen 400mg tablet. Take one dose by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoclopramide
Description: Metoclopramide 10mg tablet. Take one tablet by mouth.